Triastek Reports Positive FIH Results from Study of T21, a 3D Printed Oral Treatment for Moderate to Severe Ulcerative Colitis

The study verified the ability for Triastek’s 3D Microstructure for Colon Targeting (3DμS-CT) to precisely target and release medication in the colon NANJING, China — Triastek, Inc. (“Triastek”), a global healthcare company developing medicines with proprietary, pioneering 3D printing process, today announced Read more